ALK expands digital venture with US partnership

Allergy firm ALK has established a new collaboration in New York to persuade more US allergy patients to buy tablets from ALK.

ALK CEO Carsten Hellmann | Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

After having struggled for some time to gain footing with tablet vaccines for allergy treatments on the US market, ALK has started considering alternative sales channels.

Digital apps, online tools and the tracking of user behavior are some of the initiatives which ALK will be launching in order to persuade US allergy sufferers and allergy doctors to consider the Danish firm's tablet vaccines, which are ALK's major growth driver and source of success.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs